» Articles » PMID: 35954191

Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis

Overview
Journal Cells
Publisher MDPI
Date 2022 Aug 12
PMID 35954191
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac fibrosis is a common pathophysiologic process associated with numerous cardiovascular diseases, resulting in cardiac dysfunction. Cardiac fibroblasts (CFs) play an important role in the production of the extracellular matrix and are the essential cell type in a quiescent state in a healthy heart. In response to diverse pathologic stress and environmental stress, resident CFs convert to activated fibroblasts, referred to as myofibroblasts, which produce more extracellular matrix, contributing to cardiac fibrosis. Although multiple molecular mechanisms are implicated in CFs activation and cardiac fibrosis, there is increasing evidence that epigenetic regulation plays a key role in this process. Epigenetics is a rapidly growing field in biology, and provides a modulated link between pathological stimuli and gene expression profiles, ultimately leading to corresponding pathological changes. Epigenetic modifications are mainly composed of three main categories: DNA methylation, histone modifications, and non-coding RNAs. This review focuses on recent advances regarding epigenetic regulation in cardiac fibrosis and highlights the effects of epigenetic modifications on CFs activation. Finally, we provide some perspectives and prospects for the study of epigenetic modifications and cardiac fibrosis.

Citing Articles

Decoding the regulatory roles of circular RNAs in cardiac fibrosis.

You Q, Yu J, Pan R, Feng J, Guo H, Liu B Noncoding RNA Res. 2025; 11:115-130.

PMID: 39759175 PMC: 11697406. DOI: 10.1016/j.ncrna.2024.11.007.


Epigenetic Regulation in Myocardial Fibroblasts and Its Impact on Cardiovascular Diseases.

Komal S, Gao Y, Wang Z, Yu Q, Wang P, Zhang L Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458994 PMC: 11510975. DOI: 10.3390/ph17101353.


The Pathogenic Mechanisms of and Novel Therapies for Lamin A/C-Related Dilated Cardiomyopathy Based on Patient-Specific Pluripotent Stem Cell Platforms and Animal Models.

Wu X, Lee Y, Lau Y, Au K, Tse Y, Ng K Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204134 PMC: 11357512. DOI: 10.3390/ph17081030.


Inhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development.

Khalaji A, Mehrtabar S, Jabraeilipour A, Doustar N, Rahmani Youshanlouei H, Tahavvori A Ther Adv Cardiovasc Dis. 2024; 18:17539447241253134.

PMID: 38819836 PMC: 11143841. DOI: 10.1177/17539447241253134.


Progress and prospect of nanotechnology for cardiac fibrosis treatment.

Gaytan S, Beaven E, Gadad S, Nurunnabi M Interdiscip Med. 2023; 1(4):e20230018.

PMID: 38089921 PMC: 10712437. DOI: 10.1002/INMD.20230018.


References
1.
Li G, Shao Y, Guo H, Zhi Y, Qiao B, Ma K . MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling. Cardiovasc Res. 2021; 118(9):2139-2151. PMC: 9302889. DOI: 10.1093/cvr/cvab248. View

2.
Li C, Li J, Xue K, Zhang J, Wang C, Zhang Q . MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J Mol Cell Cardiol. 2019; 129:281-292. DOI: 10.1016/j.yjmcc.2019.03.005. View

3.
Tao H, Dai C, Ding J, Yang J, Ding X, Xu S . Epigenetic aberrations of miR-369-5p and DNMT3A control Patched1 signal pathway in cardiac fibrosis. Toxicology. 2018; 410:182-192. DOI: 10.1016/j.tox.2018.08.004. View

4.
Yun M, Wu J, Workman J, Li B . Readers of histone modifications. Cell Res. 2011; 21(4):564-78. PMC: 3131977. DOI: 10.1038/cr.2011.42. View

5.
Ghosh A . FAT-free p300 is good for scar-free tissue repair. J Cell Biochem. 2014; 115(9):1486-9. DOI: 10.1002/jcb.24820. View